Indirubin, the active constituent of a Chinese antileukaemia medicine, inhibits cyclin-dependent kinases

Abstract

loading...

About

This paper, published in 1950, received 678 indexed citations. Written by Sophie Leclerc, Jane Endicott, Alison M. Lawrie, Paul Tunnah, Maryse Leost, Eve Damiens, Dominique Marie, Doris Marko, Ellen Niederberger and Weici Tang covering the research area of Organic Chemistry, Molecular Biology and Genetics. It is primarily cited by scholars working on Molecular Biology (362 citations), Organic Chemistry (346 citations) and Oncology (140 citations). Published in Nature Cell Biology.

In The Last Decade

doi.org/10.1038/9035 →

Countries where authors are citing Indirubin, the active constituent of a Chinese antileukaemia medicine, inhibits cyclin-dependent kinases

Since Specialization
Citations

This map shows the geographic impact of Indirubin, the active constituent of a Chinese antileukaemia medicine, inhibits cyclin-dependent kinases. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Indirubin, the active constituent of a Chinese antileukaemia medicine, inhibits cyclin-dependent kinases with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Indirubin, the active constituent of a Chinese antileukaemia medicine, inhibits cyclin-dependent kinases more than expected).

Fields of papers citing Indirubin, the active constituent of a Chinese antileukaemia medicine, inhibits cyclin-dependent kinases

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of Indirubin, the active constituent of a Chinese antileukaemia medicine, inhibits cyclin-dependent kinases. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the Indirubin, the active constituent of a Chinese antileukaemia medicine, inhibits cyclin-dependent kinases.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

This paper is also available at doi.org/10.1038/9035.

Explore hit-papers with similar magnitude of impact

Rankless by CCL
2026